8-K ·Filed May 26, 2026

CGON

CG Oncology, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed4mo ago SEC0001193125-26-237908
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Monitor the Chief Commercial Officer search and any updates on commercial strategy execution. No immediate trading catalyst from this organizational change.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
CGON ▲ +30.36% at T+60d
NEUTRAL call ✓ call won +30.36% · α vs SPY +27.64% · entry $61.89 → $80.68
Entry anchored
May 26, 05:52 AM ET
via exchange tick
T+1d
-1.76%
call -1.76% · α -1.77%
$60.80
settled 4mo ago
T+5d
-4.30%
call -4.30% · α -5.38%
$59.23
settled 4mo ago
T+20d
+13.50%
call +13.50% · α +15.45%
$70.25
settled 3mo ago
T+60d
+30.36%
call +30.36% · α +27.64%
$80.68
settled 6w ago

Price Chart

Loading chart...

Executive Summary

CG Oncology announced the departure of President & COO Ambaw Bellete, effective June 30, 2026, and appointed CEO Arthur Kuan as President in addition to his existing roles. The company has initiated a search for a Chief Commercial Officer. This is a routine executive reorganization with no material financial impact.

Key Facts

  • President & COO Ambaw Bellete agreed to separation effective June 30, 2026
  • CEO Arthur Kuan appointed as President in addition to his current positions
  • Company initiated search for a Chief Commercial Officer
  • Bellete will receive severance benefits per existing employment agreement

Financial Impact

No financial figures disclosed; severance is contractual and routine

Risk Factors

  • Potential disruption from COO departure during commercial build-out
  • Key-person concentration risk as CEO adds President role

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
95% bullish (21 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-237908
Document: 0001193125-26-237908-index-headers.html0001193125-26-237908
Document: 0001193125-26-237908-index.html0001193125-26-237908
Document: 0001193125-26-237908.txt0001193125-26-237908
17 reports for CGON
Performance horizon
100% Hit rate 6 of 6 directional calls best @ T+20▲ +26.33%Jun 12, 2026
Filters
Rows
Reports for CGON — sortable, filterable
TypeNow
Aug 6, 2026
8w ago
Press Release
BEARISH ★ 7/10
$74.85 $74.33▲ +0.69%▲ +1.29%$67.38 (+9.98%)
Aug 6, 2026
8w ago
424B5
BEARISH ★ 6/10
$74.85 $74.33▲ +0.69%▲ +1.29%$67.38 (+9.98%)
Jul 27, 2026
9w ago
Press Release
BULLISH ★ 7/10
$72.62 $78.95▲ +8.72%▲ +5.34%$67.38 (−7.22%)
Jul 17, 2026
11w ago
Insider Cluster
NEUTRAL ★ 2/10
$71.85 $75.03▲ +4.43%▼ −0.02%$67.38 (−6.22%)
Jul 16, 2026
11w ago
Court Ruling
NEUTRAL ★ 4/10
$69.50 $74.71▲ +7.50%▲ +3.88%$67.38 (−3.05%)
Jun 24, 2026
14w ago
144
NEUTRAL ★ 2/10
$72.84 $71.12▼ −2.36%▼ −2.89%$67.38 (−7.50%)
Jun 22, 2026
14w ago
144
NEUTRAL ★ 3/10
$65.73 $70.19▲ +6.79%▲ +5.63%$67.38 (+2.51%)
Jun 12, 2026
16w ago
Institutional Cluster
BULLISH ★ 6/10
$59.56 $75.24▲ +26.33%▲ +24.55%$67.38 (+13.13%)
May 26, 2026
18w ago
8-K
NEUTRAL ★ 3/10
$61.89 $70.25▲ +13.50%▲ +15.45%$67.38 (+8.87%)
May 15, 2026
20w ago
Press Release
BULLISH ★ 6/10
$66.93 $59.56▼ −11.01%▼ −13.13%$67.38 (+0.67%)
Showing 10 of 17

US Market Status

Market Closed — Opens Mon (39h 28m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access